RXRX vs SAP
Recursion Pharmaceuticals Inc (RXRX) versus SAP (SAP) — a side-by-side from cached financials, not a winner call.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
SAP (SAP) common stock.
Latest reported RXRX revenue for 2026-06-30 was $14.1M. Net income was -$248.5M. RXRX currently screens at market cap $1.75B.
SAP does not have a complete income-statement cache yet.
RXRX currently screens at market cap $1.75B. SAP currently screens at market cap $0.
Not investment advice. Open the RXRX and SAP stock pages for the full models.
Not investment advice.